Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Aristotle University Of Thessaloniki
Age
29–80
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Consecutive primary open-angle (POAG) and exfoliative glaucoma (XFG) patients will be recruited.
Patients included will be older than 29 years
Have early to moderate POAG, or XFG (less than 12 mean deviation visual field loss attributed to glaucoma and 0.8 or better vertical cup-to-disc ratio)
Will be on therapy with latanoprost for more than 3 months;
Have at treated baseline IOP at 10:00 (two consecutive readings) greater than 21 mm Hg
Have a reliable visual field (at least two visual fields with less than 30% fixation losses, false positives or negatives)
Have a best corrected distance Snellen visual acuity \> 1/10
Have corneal pachymetry within the 550 ± 55 μm range, understand the study instructions and are willing to attend all follow-up appointments
Are willing to comply with study medication usage
And have open, normal appearing angles
You may not be if
Patients will be excluded if they have: a risk for significant deterioration during the study
Known previous history of lack of adequate response (\< 10% reduction) to any topical glaucoma medication
Less than 20% daytime IOP reduction on latanoprost;
Systemic contraindications to topical beta-blockers (asthma, bradycardia, severe congestive heart disease)
Known contraindications to prostaglandins, history of ocular herpetic disease, or cystoid macular edema
History of trauma, inflammation, surgery or past use of steroids (within two months)
Severe dry eyes
Use of contact lenses
Signs of ocular infection, except blepharitis
Corneal abnormality that may affect IOP measurements
Unwillingness to accept the risk for hyperchromia of the iris or development of hypertrichosis
And females of childbearing potential or lactating mothers
Clareo Health | 24-hour Study of Dorzolamide/Timolol and Latanoprost/Timolol Fixed Combinations
